Hepatic Cirrhosis
7 drugs803 FAERS reportsMedDRA PT
GET
/api/v1/reaction/hepatic-cirrhosisReference statistics only. FAERS reports are voluntarily submitted and are not incidence rates, safety signals, or causal evidence. The drugs below are ranked by how often this reaction appears on FAERS reports for each drug — high share does not mean the drug caused the reaction, and absence from this list does not mean the reaction never occurred. This is not a symptom checker.
DefinitionNLM MeSH D008103
Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules.
Source: U.S. National Library of Medicine — MeSH (Liver Cirrhosis)
Drugs reporting Hepatic Cirrhosis (7)
Share = reports listing this reaction ÷ total matched reports for the drug. — means the upstream totals query failed at ingest and the denominator is unknown.
- 1Becaplermin1100%
- 2Insulin Icodec125%
- 3Afamelanotide15.3%
- 4Resmetirom714.7%
- 5Nitisinone373.9%
- 6Rifaximin6763.3%
- 7Voxilaprevir161.5%
Related reactions
Other reactions most often co-reported on the same drug set. Ranked by Jaccard similarity over drug-id sets — pure data-derived co-occurrence, not a clinical relationship.
- Hepatic Encephalopathy2 shared · 0.18
- Ammonia Increased2 shared · 0.15
- Hepatic Failure2 shared · 0.12
- Hepatocellular Carcinoma2 shared · 0.11
- Liver Disorder2 shared · 0.10
- Cataract2 shared · 0.04
- Ascites2 shared · 0.04
- Therapy Interrupted2 shared · 0.04
- Hepatic Enzyme Increased2 shared · 0.04
- Abdominal Discomfort2 shared · 0.01
Literature
Recent PubMed references pinned to Liver Cirrhosis as a MeSH major topic. About the reaction term itself — not about any specific drug.
- Zinc deficiency and sarcopenia define a metabolic frailty phenotype predicting hepatic encephalopathy and early mortality in cirrhosis.Metabolic brain disease · 2026 · Méndez-Guerrero O, Carranza-Carrasco A, Guerrero-Guerrero R, et al.PMID 42207388DOI 10.1007/s11011-026-01879-9
- Learning ordinal representation across MRI sequences for liver fibrosis staging.Medical physics · 2026 · Huo J, Wang Y, Wu N, et al.PMID 42206568DOI 10.1002/mp.70504
- Strategies to promote liver fibrosis amelioration with involvement of restorative macrophages.Frontiers in immunology · 2026 · Aquino JBPMID 42206026DOI 10.3389/fimmu.2026.1792423
- Hepatitis E Virus Infection as a Trigger of Hepatic Decompensation: A Single-Center Prospective and Cross-Sectional Study From Rosario, Argentina.Journal of medical virology · 2026 · Acosta J, Galimberti A, Bessone F, et al.PMID 42204872DOI 10.1002/jmv.70988
- 1-Naphthol Drives Liver Steatosis and Fibrosis via the CA3-CD36 Axis Independent of Obesity.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026 · Chen R, Zeng Y, Li Y, et al.PMID 42201771DOI 10.1096/fj.202504464R
- NUDT21 Downregulation Promotes Liver Fibrosis by Activating the PIM2-Mediated CEBPB/SLC2A1 Glycolytic Axis in Hepatic Stellate Cells.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026 · Xiong M, Huang S, Li Y, et al.PMID 42201665DOI 10.1096/fj.202600255RR
Note. FAERS reports are voluntarily submitted and are NOT incidence rates, signals, or causal evidence. Counts reflect reporting volume, not how often a reaction occurs. Reference statistics only.